Key facts
- This page summarizes Bradford Crutchfield's Form 4 filing for 10x Genomics, Inc. (TXG).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 25 May 2022, 18:28.
Bradford Crutchfield - 23 May 2022 Form 4 Insider Report for 10x Genomics, Inc. (TXG)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- TXG
- Reported as of
- 23 May 2022
- Net transaction value
- -$13,947
- SEC form
- 4
- Accepted by SEC
- 25 May 2022, 18:28:46 UTC
- Prior SEC filing
- 17 May 2022
- Next SEC filing
- 25 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Eric S. Whitaker, as Attorney-in-Fact for Bradford Crutchfield
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Bradford Crutchfield filed Form 4 for 10x Genomics, Inc. (TXG) on 25 May 2022.
Change
- Previous filing in this sequence was filed on 17 May 2022.
- Current net transaction value: -$13,947.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TXG
transaction
Class A Common Stock
Sale
- Transaction value
- $13,947
- Shares
- -286
- Change %
- -0.29%
- Price
- $48.76
- Shares after
- 97,237
- Date
- 23 May 2022
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.